ArticleBMC gastroenterology2025
A Notch signal pathway related gene signature predicts overall survival in colorectal cancer.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is a prevalent malignancy worldwide, characterized by high morbidity and mortality rates. The notch signaling pathway plays a dual role as both a tumor suppressor and promoter during embryonic development. However, the precise role and underlying mechanisms of notch signal pathway-related genes in CRC remain unclear.
methodsIn this study, a prognostic signature for CRC was established using CRC datasets from The Cancer Genome Atlas (TCGA) as the training datasets and two Gene Expression Omnibus (GEO) datasets for external validation. The limma R package was first used to screen the differentially expressed genes (DEGs) of the Notch pathway in CRC from TCGA datasets. The univariate Cox regression analysis identified 12 Notch pathway related genes (NPRG) that were significantly associated with overall survival (OS) in CRC. Next, the least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analysis were used to establish a 2-gene prognostic signature (HEYL & WNT5A). Receiver operating characteristic (ROC) curve showed that the 2-gene prognostic signature could effectively predict the 1-, 2-, and 3-year survival time of CRC patients. In addition, the prognostic value of the 2-gene signature was validated in two GEO CORD&READ cohorts. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed to explore the signaling pathways and cellular processes associated with the 2-gene signature. A nomogram for predicting the OS of CRC patients was constructed by integrating clinical characteristics and the 2-gene NPRG signature, followed by validation using calibration curves and decision curve analysis (DCA) plots.
resultsThe NPRG prognostic signature for CRC was established. HEYL and WNT5A were identified as hub genes of the Notch pathway in CRC. HEYL was significantly up-regulated in the high-risk group, while WNT5A was significantly up-regulated in the low-risk group. High expression of HEYL was associated with a poorer prognosis of CRC. Furthermore, Knockout of HEYL significantly inhibited the proliferation of CRC cells in HCT116 and RKO cell lines in vitro experiments.
conclusionsOur research suggests that the 2-gene signature described here can serve as a reliable prognostic biomarker for predicting the prognosis of CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.